Radiotheranostics

Global Radiotheranostics Market to Reach US$22.4 Billion by 2030

The global market for Radiotheranostics estimated at US$10.4 Billion in the year 2024, is expected to reach US$22.4 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Targeted Diagnostics, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.8 Billion by the end of the analysis period. Growth in the Targeted Therapeutics segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.0% CAGR

The Radiotheranostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Radiotheranostics Market - Key Trends & Drivers Summarized

What Is Propelling Radiotheranostics to the Forefront of Precision Medicine?

Radiotheranostics, a cutting-edge approach that combines diagnostic imaging with targeted radiotherapy, is emerging as a game-changer in personalized medicine. This dual-function technology enables precise tumor identification and tailored treatment using radiopharmaceutical agents, minimizing damage to healthy tissues. As cancer prevalence continues to rise globally, radiotheranostics is gaining traction for its ability to provide more effective and less invasive treatment options. Furthermore, the integration of radiotheranostics into nuclear medicine is revolutionizing oncology, offering patients better outcomes and quality of life. The growing shift toward precision medicine is reinforcing its adoption, making radiotheranostics a pivotal tool in the fight against cancer.

How Is Innovation Redefining the Scope of Radiotheranostics?

Technological advancements are playing a central role in expanding the capabilities of radiotheranostics. The development of novel radiopharmaceuticals, such as theranostic isotopes like lutetium-177 and actinium-225, is enabling higher precision in both imaging and therapy. Advances in molecular imaging technologies, including PET/CT and SPECT/CT, are improving the accuracy of disease diagnosis and treatment monitoring. Additionally, artificial intelligence and machine learning are being incorporated into radiotheranostic workflows to enhance imaging interpretation and optimize treatment planning. These innovations are not only driving clinical success but also encouraging pharmaceutical companies and research institutions to invest heavily in radiotheranostics development.

What Are the Emerging Applications and Trends in Radiotheranostics?

The application of radiotheranostics is rapidly expanding beyond oncology, where it has demonstrated remarkable success in treating prostate cancer and neuroendocrine tumors. Researchers are exploring its potential in addressing other diseases, such as cardiovascular conditions and certain infectious diseases, by leveraging its ability to target specific biological pathways. An emerging trend is the use of combination therapies, where radiotheranostics is paired with immunotherapy or chemotherapy to amplify treatment efficacy. Furthermore, advancements in radiopharmaceutical production and supply chain logistics are addressing scalability challenges, ensuring that these therapies are more widely available to patients across diverse healthcare settings.

What Drives the Rapid Growth in the Radiotheranostics Market?

The growth in the Radiotheranostics market is driven by several factors. Increasing cancer incidence worldwide has heightened the need for innovative treatment modalities, making radiotheranostics a critical focus area. Significant advancements in radiopharmaceutical development and molecular imaging technologies have enhanced the efficacy and accessibility of these treatments. Rising investments in nuclear medicine infrastructure and expanding healthcare budgets in developing regions are also accelerating market growth. Additionally, the growing preference for personalized treatment approaches among both patients and healthcare providers is boosting the adoption of radiotheranostics. Regulatory support and favorable reimbursement policies further contribute to the widespread adoption of this promising technology, cementing its role in the future of precision medicine.

SCOPE OF STUDY:

The report analyzes the Radiotheranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Modality (Targeted Diagnostics, Targeted Therapeutics); Radioisotope (Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope, Other Radioisotopes); Application (Oncology Application, Non-Oncology Application)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

• Actinium Pharmaceuticals, Inc.
• Ariceum Therapeutics
• Bayer AG
• Cardinal Health, Inc.
• Curium
• Ellipses Pharma
• GE Healthcare
• ImmunoMet Therapeutics
• Life Healthcare
• Life Molecular Imaging GmbH

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.